Business
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
MIAMI, January 06, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present...
About this update from Summit Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":292,"url":"https://media.zenfs.com/en/business-wire.com/e7b0ebefd354f1a700599b570fa93d81"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3uXzM5ZHBwC08QWUcoCaVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU4NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e7b0ebefd354f1a700599b570fa93d81","width":480,"height":292}},"lazy":false},{"type":"text","content":"MIAMI, January 06, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 12, 2026 at 9:45 AM PT. Robert W. Duggan, Chairman and Co-Chief Executive Officer, and Dr. Maky Zanganeh, President and Co-Chief Executive Officer, will present a corporate overview and a new update on the progress of our organization, including the development of our innovative investigational bispecific antibody, ivonescimab. Our leadership team will also participate in investor meetings during the conference.","length":720,"tagName":"p"},{"type":"text","content":"The presentation will be available live from our website: www.smmttx.com. An archived version of the presentation will be available on our website following the presentation.","length":174,"tagName":"p"},{"type":"text","content":"About Ivonescimab","length":17,"tagName":"p"},{"type":"text","content":"Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF.","length":573,"tagName":"p"},{"type":"text","content":"This is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microe...